HER2 status-Positive Posts on Medivizor
Navigation Menu

HER2 status-Positive Posts on Medivizor

Comparing the effectiveness and safety of trastuzumab emtansine plus pertuzumab versus taxane plus trastuzumab plus pertuzumab in patients with high-risk HER2+ early breast cancer.

Comparing the effectiveness and safety of trastuzumab emtansine plus pertuzumab versus taxane plus trastuzumab plus pertuzumab in patients with high-risk HER2+ early breast cancer.

Posted by on Apr 14, 2022 in Breast cancer | 0 comments

In a nutshell This study compared the effectiveness and safety of trastuzumab emtansine (T-DM1; Kadcyla) plus pertuzumab (Perjeta) versus taxanes plus trastuzumab (Herceptin) plus pertuzumab (THP) in patients with high-risk HER2-positive (+) early breast cancer (BC) after previous treatment with anthracycline-based chemotherapy. The data showed that...

Read More

Evaluating the long-term benefits and risks of trastuzumab plus chemotherapy in patients with early-stage HER2+ breast cancer.

Evaluating the long-term benefits and risks of trastuzumab plus chemotherapy in patients with early-stage HER2+ breast cancer.

Posted by on Nov 7, 2021 in Breast cancer | 0 comments

In a nutshell This study evaluated the long-term benefits and risks of trastuzumab (Herceptin) plus chemotherapy in patients with early-stage HER2-positive (+) breast cancer (BC). The data showed that trastuzumab added to chemotherapy reduced the risk of BC recurrence and death for these patients. Some background BC is classified into different...

Read More

Is pyrotinib effective as a second-line treatment in patients with HER2-positive breast cancer in a real-world setting?

Is pyrotinib effective as a second-line treatment in patients with HER2-positive breast cancer in a real-world setting?

Posted by on Oct 17, 2021 in Breast cancer | 0 comments

In a nutshell The authors evaluated the efficacy and safety of pyrotinib (Irene), for the treatment of HER2- positive metastatic breast cancer (MBC) in a real-world setting. The authors observed that pyrotinib was effective and well tolerated by patients.  Some background Breast cancer (BC) is the most common tumor in women...

Read More

Evaluating the effectiveness and safety of different anti-HER2 therapies in combination with chemotherapy for metastatic HER2-positive breast cancer.

Evaluating the effectiveness and safety of different anti-HER2 therapies in combination with chemotherapy for metastatic HER2-positive breast cancer.

Posted by on Oct 16, 2021 in Breast cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of different anti-HER2 therapies in combination with chemotherapy for the treatment of patients with metastatic HER2-positive breast cancer (BC). The data showed that THP (taxanes + trastuzumab + pertuzumab) was the best first-line treatment, while Trastuzumab emtansine (T-DM1; Kadcycla) and...

Read More

Which combination of treatments is better for HER2 positive advanced breast cancer?

Which combination of treatments is better for HER2 positive advanced breast cancer?

Posted by on Sep 17, 2021 in Breast cancer | 0 comments

In a nutshell This study compared two treatment regimes for HER2 positive breast cancer; pyrotinib (Irene) plus vinorelbine (Navelbine), or lapatinib (Tykerb) plus capecitabine (Xeloda). It found that pyrotinib plus vinorelbine (PV) improved survival without cancer progressing compared to lapatinib plus capecitabine (LC).  Some background...

Read More

Tucatinib plus trastuzumab and capecitabine preserves health-related quality of life in patients with metastatic HER2-positive breast cancer.

Tucatinib plus trastuzumab and capecitabine preserves health-related quality of life in patients with metastatic HER2-positive breast cancer.

Posted by on Sep 5, 2021 in Breast cancer | 0 comments

In a nutshell This study evaluated the impact of tucatinib (Tukysa) in combination with trastuzumab (Herceptin) and capecitabine (Xeloda) on health-related quality of life (HR-QoL) in patients with metastatic human epidermal growth factor (HER2)-positive breast cancer (BC). The data showed that this combination preserved HR-QoL in these patients. Some...

Read More

Evaluating the effects of adding chemotherapy to trastuzumab treatment on mental functioning in older patients with HER2-positive breast cancer.

Evaluating the effects of adding chemotherapy to trastuzumab treatment on mental functioning in older patients with HER2-positive breast cancer.

Posted by on Aug 29, 2021 in Breast cancer | 0 comments

In a nutshell This study investigated the effects of adding chemotherapy to trastuzumab (Herceptin) treatment on cognitive (thinking and reasoning) functioning in older patients with HER2-positive (HER2+) breast cancer (BC). The data showed that the addition of chemotherapy did not impact cognitive functioning in these women. Some...

Read More

Does neratinib plus capecitabine benefit patients with HER2-positive breast cancer spread to the central nervous system?

Does neratinib plus capecitabine benefit patients with HER2-positive breast cancer spread to the central nervous system?

Posted by on Jul 25, 2021 in Breast cancer | 0 comments

In a nutshell This study compared the safety and effectiveness of neratinib (Nerlynx) plus capecitabine (Xeloda) versus lapatinib (Tykerb) plus capecitabine in patients with human epidermal growth factor (HER2)-positive breast cancer (BC) spread (metastases) to the central nervous system (CNS; brain and spinal cord). The data showed that the...

Read More

Is pyrotinib with vinorelbine effective in treating HER2+ metastatic breast cancer?

Is pyrotinib with vinorelbine effective in treating HER2+ metastatic breast cancer?

Posted by on Jul 21, 2021 in Breast cancer | 0 comments

In a nutshell This study was carried out to examine the safety and effectiveness of pyrotinib (Irene) in combination with vinorelbine (Navelibine) is in treating metastatic breast cancer (BC). The authors found that this treatment combination showed promising results and was well tolerated in these patients.  Some background BC is...

Read More

Comparing the safety and effectiveness of pyrotinib versus trastuzumab etamsine for the treatment of HER2-positive metastatic breast cancer.

Comparing the safety and effectiveness of pyrotinib versus trastuzumab etamsine for the treatment of HER2-positive metastatic breast cancer.

Posted by on Jul 11, 2021 in Breast cancer | 0 comments

In a nutshell This study compared the safety and effectiveness between pyrotinib (SHR-1258) and trastuzumab emtansine (T-DM1; Kadcyla) in patients with HER2+ metastatic breast cancer (BC) after previous treatment with trastuzumab (Herceptin) and chemotherapy. The data showed that pyrotinib may be more effective than T-DM1 for these patients. Some...

Read More

Evaluating the final effectiveness and safety outcomes of neratinib in patients with early stage HER2+/HR+ breast cancer.

Evaluating the final effectiveness and safety outcomes of neratinib in patients with early stage HER2+/HR+ breast cancer.

Posted by on Apr 4, 2021 in Breast cancer | 0 comments

In a nutshell This study reported the final effectiveness and safety outcomes of neratinib treatment in patients with early-stage HER2+/HR+ breast cancer. The data showed that neratinib significantly improved invasive disease-free survival in these patients who initiated treatment within 1 year of trastuzumab-based therapy. Some background...

Read More
ABOUT USHOW IT WORKSBLOG NEWS PARTNERS CONTACT US PRIVACY POLICY TERMS OF USE
FROM OUR BLOG
LATEST NEWS
CONNECT WITH US
© 2024 Medivizor